Immuron Limited (ASX: IMC), an integrated biopharmaceutical company headquartered in Australia, reported the unaudited net sales results for its over-the-counter gastrointestinal and digestive health immune supplements, namely Travelan and Protectyn. In FY23, the sales of Travelan and Protectyn experienced a remarkable surge of 136%, reaching AU$1.80 million, compared to AU$765,000 in FY22.
Notably, Travelan and Protectyn sales within Australia soared to AU$1.16 million in FY23, reflecting an extraordinary increase of 478% compared to the sales figures of AU$201,000 in FY22. This growth can be attributed to the recovery of overseas travel, as evidenced by Australian resident short-term departures in April 2023, which reached 82% of the numbers recorded in April 2019, according to the Australian Bureau of Statistics. Immuron remains focused on enhancing sales of its existing commercial products, broadening its product portfolio, and leveraging its robust pipeline for future growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
